Last updated on November 2017

Allergan Migraine MD-01

Brief description of study

Allergan Migraine MD-01

Detailed Study Description

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine.

Clinical Study Identifier: TX15429

Contact Investigators or Research Sites near you

Start Over

Columbus Regional Research Institute

Columbus Regional Research Institute
Columbus, GA USA

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.